×
Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely i...
https://doi.org/10.1111/bcp.15489
British Journal of Clinical Pharmacology; Lyashchenko AK, Yu Y et. al.

Aug 13th, 2022 - To investigate the relationship between systemic exposure to Hydroxychloroquine (HCQ) and its metabolite Desethylhydroxychloroquine (DHCQ) and clinical outcome in severely ill patients treated with a standard oral dose regimen of HCQ during the first wave of COVID-19 in New York City. We correlated retrospective clinical data with drug exposure prospectively assessed from convenience samples us...

Neutrophil autophagy and NETosis in COVID-19: perspectives.
https://doi.org/10.1080/15548627.2022.2099206
Autophagy Zhang R, Sun C et. al.

Aug 12th, 2022 - The COVID-19 pandemic has caused substantial losses worldwide in people's lives, health, and property. Currently, COVID-19 is still prominent worldwide without any specific drug treatment. The SARS-CoV-2 pathogen is the cause of various systemic diseases, mainly acute pneumonia. Within the pathological process, neutrophils are recruited to infected sites, especially in the lungs, for the first ...

Comparative-effectiveness research of COVID-19 treatment: a rapid scoping review.
https://doi.org/10.1136/bmjopen-2020-045115
BMJ Open; Pham B, Rios P et. al.

Aug 11th, 2022 - The COVID-19 pandemic has stimulated growing research on treatment options. We aim to provide an overview of the characteristics of studies evaluating COVID-19 treatment. Rapid scoping review DATA SOURCES: Medline, Embase and biorxiv/medrxiv from inception to 15 May 2021. Hospital and community care. COVID-19 patients of all ages. COVID-19 treatment. The literature search identified 616 relevan...

Using Time Weighted Average Change from Baseline of SARS-CoV-2 Viral Load to Assess Imp...
https://doi.org/10.1002/jmv.28054
Journal of Medical Virology; Kumbhakar R, Neradilek M et. al.

Aug 9th, 2022 - Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either post-exposure prophylaxis (PEP) or early treatment of SARS-CoV-2 infection. Using data from these studies, we calculated time-weighted average change from baseline SARS-CoV-2 viral load and demonstrated that HCQ did not affect viral clearance. This article is protected by copyright. All righ...

Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352647
Clinical Microbiology and Infection : the Official Public... Polo R, García-Albéniz X et. al.

Aug 9th, 2022 - To assess the effect of hydroxychloroquine (HCQ) and Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC) as pre-exposure prophylaxis on COVID-19 risk. EPICOS is a double-blind, placebo-controlled randomized trial conducted in Spain, Bolivia, and Venezuela. Healthcare workers with negative SARS-CoV-2 IgM/IgG test were randomly assigned to: daily TDF/FTC plus HCQ for 12 weeks, TDF/FTC plus HCQ ...

Should RECOVERY have used response adaptive randomisation? Evidence from a simulation s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356442
BMC Medical Research Methodology; Sirkis T, Jones B et. al.

Aug 7th, 2022 - The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is aimed at addressing the urgent need to find effective treatments for patients hospitalised with suspected or confirmed COVID-19. The trial has had many successes, including discovering that dexamethasone is effective at reducing COVID-19 mortality, the first treatment to reach this milestone in a randomised controlled trial. Desp...

A Review of Clinical Efficacy Data Supporting Emergency Use Authorization for COVID-19 ...
https://doi.org/10.1111/cts.13384
Clinical and Translational Science; Yoo SH, Kim L et. al.

Aug 6th, 2022 - Emergency Use Authorization (EUA) allows the U.S. Food and Drug Administration (FDA) to expedite the availability of therapeutics in the context of a public health emergency. To date, an evidentiary standard for clinical efficacy to support an EUA has not yet been established. This review examines the clinical data submitted in support of EUA for anti-viral and anti-inflammatory therapeutics fo...

Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355221
PloS One; de Reus YA, Hagedoorn P et. al.

Aug 6th, 2022 - Inhaled antimicrobials enable high local concentrations where needed and, compared to orally administration, greatly reduce the potential for systemic side effects. In SARS-CoV-2 infections, hydroxychloroquine sulphate (HCQ) administered as dry powder via inhalation could be safer than oral HCQ allowing higher and therefore more effective pulmonary concentrations without dose limiting toxic eff...

Kikuchi Disease
http://emedicine.medscape.com/article/210752-overview

Aug 4th, 2022 - Practice Essentials Kikuchi disease, also called histiocytic necrotizing lymphadenitis or Kikuchi-Fujimoto disease, is a rare, idiopathic, generally self-limited cause of lymphadenitis. [1] Kikuchi first described the disease in 1972 in Japan. Fujimoto and colleagues independently described Kikuchi disease in the same year. [2] The cause of Kikuchi disease is unknown, although infectious and au...

Kikuchi Disease
https://emedicine.medscape.com/article/210752-print

Aug 4th, 2022 - Practice Essentials Kikuchi disease, also called histiocytic necrotizing lymphadenitis or Kikuchi-Fujimoto disease, is a rare, idiopathic, generally self-limited cause of lymphadenitis.[1] Kikuchi first described the disease in 1972 in Japan. Fujimoto and colleagues independently described Kikuchi disease in the same year.[2] The cause of Kikuchi disease is unknown, although infectious and auto...

Kikuchi Disease
https://emedicine.medscape.com/article/210752-overview

Aug 4th, 2022 - Practice Essentials Kikuchi disease, also called histiocytic necrotizing lymphadenitis or Kikuchi-Fujimoto disease, is a rare, idiopathic, generally self-limited cause of lymphadenitis. [1] Kikuchi first described the disease in 1972 in Japan. Fujimoto and colleagues independently described Kikuchi disease in the same year. [2] The cause of Kikuchi disease is unknown, although infectious and au...

Outcomes of COVID-19 and Factors Associated With Its Severity Among Hospitalized Patien...
https://doi.org/10.1097/RHU.0000000000001891
Journal of Clinical Rheumatology : Practical Reports on R... Siegel CH, Choi JM et. al.

Jul 30th, 2022 - Conflicting data exist regarding whether patients with systemic rheumatic disease (SRD) experience more severe outcomes related to COVID-19. Using data from adult patients hospitalized with COVID-19 in New York City during the first wave of the pandemic, we evaluated whether patients with SRD were at an increased risk for severe outcomes. We conducted a medical records review study including pa...

Friend or Foe? Implication of the autophagy-lysosome pathway in SARS-CoV-2 infection an...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305279
International Journal of Biological Sciences; He W, Gao Y et. al.

Jul 26th, 2022 - There is increasing amount of evidence indicating the close interplays between the replication cycle of SARS-CoV-2 and the autophagy-lysosome pathway in the host cells. While autophagy machinery is known to either assist or inhibit the viral replication process, the reciprocal effects of the SARS-CoV-2 on the autophagy-lysosome pathway have also been increasingly appreciated. More importantly, ...

COVID-19 Vaccination In Autoimmune Diseases (COVAD) Study: Vaccine Safety In Idiopathic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349921
Muscle & Nerve; Gil-Vila A, Naveen R et. al.

Jul 24th, 2022 - We studied COVID-19 vaccination-related adverse events (ADEs) 7-days post-vaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs). 7-day vaccine ADEs were collected in an international patient self-reported e-survey. Descriptive statistics and multivariable regression were performed. 10,900 respondents [1227 IIMs; 4...

Trends in COVID-19 patient characteristics in a large electronic health record database...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299343
PloS One; Liang C, Ogilvie RP et. al.

Jul 21st, 2022 - Electronic health record (EHR) databases provide an opportunity to facilitate characterization and trends in patients with COVID-19. Patients with COVID-19 were identified based on an ICD-10 diagnosis code for COVID-19 (U07.1) and/or a positive SARS-CoV-2 viral lab result from January 2020 to November 2020. Patients were characterized in terms of demographics, healthcare utilization, clinical c...

The role of treatment with plasma exchange therapy in two pediatric toxic epidermal nec...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350357
Journal of Clinical Apheresis; Varol F, Can YY et. al.

Jul 7th, 2022 - Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocutaneous reactions characterized by necrosis and detachment of the epidermis. Drugs and bacterial or viral infections are the most common causes of SJS/TEN. Although cases of SJS/TEN have been reported after hydroxychloroquine, vaccine (mRNA [Biontech], and inactivated vaccine [Sinovac]) administration...

Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, dou...
https://doi.org/10.1080/14787210.2022.2098113
Expert Review of Anti-infective Therapy; Elshafie AH, Elsawah HK et. al.

Jul 6th, 2022 - To investigate the efficacy and safety of ivermectin compared to hydroxychloroquine and placebo in hospitalized moderate to severe COVID-19 patients. The study was an adaptive, randomized, double-blinded, controlled, single-center trial. The study was a series of 3-arm comparisons between two different investigational therapeutic agents (ivermectin and hydroxychloroquine) and a placebo. There w...

Using Twitter Data to Understand Public Perceptions of Approved versus Off-label Use fo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278189
Journal of the American Medical Informatics Association :... Hua Y, Jiang H et. al.

Jul 2nd, 2022 - Understanding public discourse on emergency use of unproven therapeutics is essential to monitor safe use and combat misinformation. We developed a natural language processing (NLP)-based pipeline to understand public perceptions of and stances on COVID-19-related drugs on Twitter across time. This retrospective study included 609,189 US-based tweets between January 29th, 2020 and November 30th...

Comparison of demographic, clinical and laboratory characteristics between first and se...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240448
BMJ Open; Naushad VA, Purayil NK et. al.

Jun 30th, 2022 - To compare the patient profile and outcomes in Qatar during the first and second waves of the COVID-19 pandemic. A retrospective observational study was conducted comparing the demographic, clinical and laboratory characteristics of patients with COVID-19 infection admitted to a secondary care hospital, during the first and second waves of the pandemic. 1039 patients from the first wave and 991...

Hydroxychloroquine Risk Found in Some Older Patients With RA
https://www.medscape.com/viewarticle/976299

Jun 28th, 2022 - Hydroxychloroquine should be initiated with caution in older patients with rheumatoid arthritis (RA) who also have heart failure or are at risk for it, say the authors of a study suggesting that the drug could increase their risk for major adverse cardiovascular events (MACE) compared with methotrexate. A cohort study published online June 27 in the Journal of the American College of Cardiology...